Arca
Skip to content
Tools
Tools

Vitiligo

Drug research and approvals for vitiligo: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 43 studies of vitiligo are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 43
  • Trials authorized in Canada: 25
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 43 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 6

Phase 2 12 of 18

Phase 1 or earlier 6

How its trials ended

250 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 40 whose ending is known, 40% met their primary endpoint, 5% missed it and 55% stopped early.

  • Completed, result not reported8534%
  • Status unknown7128%
  • Ongoing5422%
  • Met its primary endpoint166%
  • Stopped: other or unclear166%
  • Stopped: enrollment or feasibility42%
  • Missed its primary endpoint21%
  • Stopped: sponsor or business decision21%

Trials authorized in Canada

The 10 newest of 25; search them all in Canada trials
Oct 22, 2026A multicnter, randomized, double-blind, placebo controlled program consisting of a phase 2b trial and phase 3 trial to evaluate the efficacy and safety of…TEV-53408Teva Canada LimitedPending
Apr 14, 2026A phase 2, randomized, 24-week, multicenter, double-blind, placebo-controlled proof-of-concept study to investigate efficacy and safety of LY4005130 in adult…LY4005130Eli LillyOngoing
Feb 2, 2026A multicenter, randomized, double-blind, placebo-controlled, dose-ranging phase IIb study to assess the efficacy and safety of GIA632 in adult participants…GIA632Novartis PharmaceuticalsOngoing
Oct 2, 2025A phase 2, multicenter, randomized, placebo-controlled, double-blind, dose ranging trial to evaluate the efficacy and safety of zasocitinib in participants…Zasocitinib (TAK-279)Takeda Pharmaceuticals USAOngoing
Nov 5, 2024A phase 3, randomized, double-blind, safety, and efficacy study of ruxolitinib cream in pediatric participants with nonsegmental vitiligoRuxolitinibIncyteOngoing
May 24, 2024A randomized, double-blind, vehicle controlled phase 2b trial evaluating the efficacy, safety & pharmacokinetics of VYN201 gel in the treatment of…VYN201VYNE TherapeuticsOngoing
Dec 18, 2023A phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and tolerability of upadacitinib in adult and adolescent…Upadacitinib (ABT-494)AbbVieOngoing
Nov 27, 2023A phase 3 randomized withdrawal and dose-up titration, multi-center extension study investigating the safety, efficacy, and tolerability of ritlecitinib…Ritlecitinib (PF-06651600)PfizerOngoing
Oct 23, 2023A phase 3 randomized, double-blind, 52-week placebo-controlled multi-center study with a double-blind 52-week extension period with randomized dose up/dose…Ritlecitinib (PF-06651600)PfizerOngoing
Oct 4, 2023A phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-6194 in adult participants with non-…MK-6194Merck & Co. (MSD)Ongoing

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 19, 2023OpzeluraRuxolitinibIncyte Biosciences Distribution B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.